Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech - portfolio companies reported many important R&D milestones

The second quarter was distinguished by a difficult macroeconomic environment and, particularly, by stubbornly high inflation. The broad market corrections that began earlier in the year continued. Despite the clearly risk-off sentiment in the broader investment community, the companies in BB Biotech's portfolio reported many important R&D milestones, including late-stage clinical trial results. Learn more in the video update with Dr. Daniel Koller, Head Investment Management Team BB Biotech.
22.07.2022 - Daniel Koller
Video Update Q2 Results (EN)